Posted by Michael Wonder on 06 Mar 2023
Ikena Oncology receives FDA fast track designation for novel AHR antagonist IK-175 in combination with nivolumab to treat urothelial carcinoma
6 March 2023 - Ikena Oncology today announced that the US FDA has granted fast track designation for IK-175, the Company’s novel aryl hydrocarbon receptor antagonist, in combination with immune checkpoint inhibitors in patients with advanced urothelial carcinoma who have progressed on or within three months of receiving the last dose of checkpoint inhibitors.
IK-175 is the second of Ikena’s candidates to receive fast track designation; the FDA has also granted the designation to IK-930, the Company’s novel TEAD inhibitor, in patients with unresectable NF2 deficient malignant pleural mesothelioma.
